Arab Pharmaceuticals

مادة اعلانية

Latest Update: 17 Sep 2024 15:05 Abu Dhabi Time.

Market Status: Closed

ADCI

Arab Pharmaceuticals

88.00

EGP

-3.480

-3.80%

Open

91.48

Prev Close

91.48

PX_VOLUME

526

MARKET CAP (M)

548.88

DAY RANGE

86.00 - 89.89

52 WEEKS

56.00 - 98.00

Stock Statistics

Yearly Change

52.14%

Listed Shares (Million)

6.00

Earnings Multiple

5.34

Average 30-day trading volume

1,702.89

Price-to-book ratio

1.20

Earnings Per Share

17.14

Previous Dividend Distribution

4.28

Dividend Yield

5.49%

Financial Summary

Quarterly
Annual

Income Statements

	Period Ending:	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022
Total Revenue		204.44	167.19	222.66	191.24	148.58	160.19	171.02
Gross Profit		68.62	44.23	87.45	65.69	41.79	53.34	64.71
Operating Income		23.44	10.37	45.64	33.77	6.73	18.95	30.62
Profit Margin		9.94	10.06	17.19	14.34	7.04	9.73	14.91

	Period Ending:	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019
Total Revenue		785.52	633.73	505.04	537.05	521.07	436.35
Gross Profit		265.99	224.35	185.43	230.30	213.96	140.52
Operating Income		118.10	94.76	89.82	122.16	114.87	54.96
Profit Margin		13.09	13.06	15.11	18.88	17.81	9.88

Balance Sheet

	Period Ending:	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022
Total Assets		1,133.59	1,100.14	1,057.19	732.60	682.07	653.00	660.99
Total Liabilities		675.06	657.93	645.23	321.95	298.84	278.38	305.50
Total Equity		458.53	442.21	411.96	410.65	383.23	374.61	355.49

	Period Ending:	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020	Jun 30, 2019
Total Assets		1,133.59	682.07	573.98	446.27	371.83	298.59
Total Liabilities		675.06	298.84	233.78	136.63	123.05	109.09
Total Equity		458.53	383.23	340.21	309.63	248.79	189.50

Cash Flows Statements - Coming Soon

* In Million of Egypt Pound

Reminder: The financial information on this website is delayed information that are originates from certified data providers in the financial markets, who retain the rights and intellectual property of this data, absolving ADMN of any responsibility.